51
|
Seger S, Stritt M, Vezzali E, Nayler O, Hess P, Groenen PMA, Stalder AK. A fully automated image analysis method to quantify lung fibrosis in the bleomycin-induced rat model. PLoS One 2018; 13:e0193057. [PMID: 29547661 PMCID: PMC5856260 DOI: 10.1371/journal.pone.0193057] [Citation(s) in RCA: 32] [Impact Index Per Article: 5.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/13/2017] [Accepted: 02/02/2018] [Indexed: 12/04/2022] Open
Abstract
Intratracheal administration of bleomycin induces fibrosis in the lung, which is mainly assessed by histopathological grading that is subjective. Current literature highlights the need of reproducible and quantitative pulmonary fibrosis analysis. If some quantitative studies looked at fibrosis parameters separately, none of them quantitatively assessed both aspects: lung tissue remodeling and collagenization. To ensure reliable quantification, support vector machine learning was used on digitalized images to design a fully automated method that analyzes two important aspects of lung fibrosis: (i) areas having substantial tissue remodeling with appearance of dense fibrotic masses and (ii) collagen deposition. Fibrotic masses were identified on low magnification images and collagen detection was performed at high magnification. To insure a fully automated application the tissue classifier was trained on several independent studies that were performed over a period of four years. The detection method generates two different values that can be used to quantify lung fibrosis development: (i) percent area of fibrotic masses and (ii) percent of alveolar collagen. These two parameters were validated using independent studies from bleomycin- and saline-treated animals. A significant change of these lung fibrosis quantification parameters- increased amount of fibrotic masses and increased collagen deposition- were observed upon intratracheal administration of bleomycin and subsequent significant beneficial treatments effects were observed with BIBF-1120 and pirfenidone.
Collapse
Affiliation(s)
- Shanon Seger
- Drug Discovery Biology, Idorsia Pharmaceuticals Ltd. Hegenheimermattweg, CH, Allschwil, Switzerland
- * E-mail:
| | - Manuel Stritt
- Drug Discovery Biology, Idorsia Pharmaceuticals Ltd. Hegenheimermattweg, CH, Allschwil, Switzerland
| | - Enrico Vezzali
- Drug Discovery Pharmacology, Idorsia Pharmaceuticals Ltd. Hegenheimermattweg, CH, Allschwil, Switzerland
| | - Oliver Nayler
- Drug Discovery Biology, Idorsia Pharmaceuticals Ltd. Hegenheimermattweg, CH, Allschwil, Switzerland
| | - Patrick Hess
- Drug Discovery Pharmacology, Idorsia Pharmaceuticals Ltd. Hegenheimermattweg, CH, Allschwil, Switzerland
| | - Peter M. A. Groenen
- Drug Discovery Biology, Idorsia Pharmaceuticals Ltd. Hegenheimermattweg, CH, Allschwil, Switzerland
| | - Anna K. Stalder
- Drug Discovery Biology, Idorsia Pharmaceuticals Ltd. Hegenheimermattweg, CH, Allschwil, Switzerland
| |
Collapse
|
52
|
Meziani L, Mondini M, Petit B, Boissonnas A, Thomas de Montpreville V, Mercier O, Vozenin MC, Deutsch E. CSF1R inhibition prevents radiation pulmonary fibrosis by depletion of interstitial macrophages. Eur Respir J 2018; 51:51/3/1702120. [PMID: 29496785 DOI: 10.1183/13993003.02120-2017] [Citation(s) in RCA: 109] [Impact Index Per Article: 18.2] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/10/2017] [Accepted: 12/04/2017] [Indexed: 11/05/2022]
Abstract
Radiation-induced lung fibrosis (RIF) is a delayed side-effect of chest radiotherapy, frequently associated with macrophage infiltration.We aimed to characterise the role of pulmonary macrophages in RIF using human lung biopsies from patients receiving radiotherapy for thorax malignancies and a RIF model developed in C57BL/6 mice after 16-Gy thorax irradiation.High numbers of macrophages (both interstitial and alveolar) were detected in clinical and preclinical RIF. In the preclinical model, upregulation of T-helper (Th)2 cytokines was measured, whereas Th1 cytokines were downregulated in RIF tissue lysate. Bronchoalveolar lavage demonstrated upregulation of both types of cytokines. At steady state, tissue-infiltrating macrophages (IMs) expressed 10-fold more arginase (Arg)-1 than alveolar macrophages (AMs), and a 40-fold upregulation of Arg-1 was found in IMs isolated from RIF. IMs, but not AMs, were able to induce myofibroblast activation in vitro In addition, whereas depletion of AMs using Clodrosome didn't affect RIF score, depletion of IMs using a clinically available colony-stimulating factor receptor-1 (CSF1R) neutralising antibody was antifibrotic.These findings suggest differential contributions of alveolar versus interstitial macrophages in RIF, highlighting the fibrogenic role of IMs. The CSF1/CSF1R pathway was identified as a new therapeutic target to inhibit RIF.
Collapse
Affiliation(s)
- Lydia Meziani
- Gustave Roussy, Université Paris-Saclay, Inserm U1030, Villejuif, France.,Labex LERMIT, DHU TORINO, SIRIC SOCRATE
| | - Michele Mondini
- Gustave Roussy, Université Paris-Saclay, Inserm U1030, Villejuif, France.,Labex LERMIT, DHU TORINO, SIRIC SOCRATE
| | - Benoît Petit
- Radio-Oncology Laboratory, Dept of Radiation Oncology/DO/CHUV, Lausanne University Hospital, Lausanne, Switzerland
| | - Alexandre Boissonnas
- INSERM, U1135, F-75013, Paris, France.,Université Pierre et Marie Curie, Faculté de médecine, Paris, France
| | - Vincent Thomas de Montpreville
- Labex LERMIT, DHU TORINO, SIRIC SOCRATE.,Service d'Anatomie Pathologique, Hôpital Marie Lannelongue, Le Plessis Robinson, France
| | - Olaf Mercier
- Labex LERMIT, DHU TORINO, SIRIC SOCRATE.,Service de Chirurgie thoracique, Hôpital Marie Lannelongue, Le Plessis Robinson, France
| | - Marie-Catherine Vozenin
- Radio-Oncology Laboratory, Dept of Radiation Oncology/DO/CHUV, Lausanne University Hospital, Lausanne, Switzerland .,These authors contributed equally
| | - Eric Deutsch
- Gustave Roussy, Université Paris-Saclay, Inserm U1030, Villejuif, France .,Labex LERMIT, DHU TORINO, SIRIC SOCRATE.,Gustave Roussy, Université Paris-Saclay, Departement de radiotherapie, Villejuif, France.,These authors contributed equally
| |
Collapse
|